Incannex #Healthcare Limited, a clinical-stage pharmaceutical company developing unique #medicinal #cannabis #pharmaceutical products and #psychedelic medicine therapies for unmet medical needs, announced that #American Depositary Shares (‘ADS’) representing its ordinary shares have commenced trading on the #Nasdaq #Global #Market. Incannex simultaneously retains its listing of ordinary shares on the #Australian #Stock however, by achieving a dual listing on Nasdaq, the company is now more accessible to a wider audience of investors with sophisticated understandings of medicinal #cannabinoids, psychedelic #therapies, and pharmaceutical development.
Incannex completed the Nasdaq listing without an associated #capital raise in the #UnitedStates. Therefore, initial trading of ADSs may be limited due to the time it takes for existing shareholders to transition their IHL ordinary shares to ADSs. #Deutsche #Bank Trust Company Americas has been appointed depositary, custodian, and registrar for the Company’s American Depositary Receipt program. Joel Latham, Managing Director and Chief #Executive Officer of Incannex, and Troy Valentine, #Chairman of Incannex were invited to ring the closing bell “The ringing of the closing bell to commemorate the listing of our ADSs was a milestone for Incannex, as we advance our pipeline of novel #synthetic cannabinoid and psychedelic #agents through the #clinic,” stated Mr. Latham.
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of generalized #anxiety disorder, obstructive #sleep #apnoea, #traumatic #brain injury and more. Incannex trades on the Nasdaq under the ticker symbol ‘IXHL’.